Anika Therapeutics (ANIK) as of March 31, 2026 presents a balance sheet where liquidation recovery to equity is marginally positive on an operating liquidation basis per MFFAIS estimates ($44.9M OLV) but compressed by active cash consumption and significant non-cash intangible/goodwill exposure. Total assets of $179.4M are anchored by cash of $41.0M (100% recovery), accounts receivable net $25.8M (90-95% recovery), inventory net $22.8M plus $3.8M noncurrent (60% recovery on ~$26.6M combined = ~$16M), and PP&E net $39.7M (50-70% recovery = $20-28M). Intangibles net $1.65M receive 0% under the liquidation lens; goodwill of $7.9M is also zeroed. Operating ROU asset of $25.4M receives no value but the corresponding lease liabilities of $25.7M ($1.9M current + $23.8M noncurrent) remain at face value, a meaningful liability stack. Total current liabilities are $21.0M; total liabilities implied at approximately $45.5M. Stockholders' equity on a GAAP basis is $133.9M, but after applying liquidation haircuts the picture narrows considerably. The primary asset-side destruction is: goodwill and intangibles zeroed (~$9.5M), PP&E haircut (~$10-20M loss vs. net book), inventory haircut (~$10M loss), and ROU asset zeroed (~$25M) while lease liability persists. Cash has declined from $57.5M at December 31, 2025 to $41.0M, a $16.5M reduction in one quarter driven by $8.7M in share repurchases, $4.8M operating outflows (primarily inventory build and AR growth), and $1.4M capex. The share repurchase program was substantially completed in April 2026 ($15M Clear Street tranche), so the cash burn from buybacks is largely concluded but cash is now at a level that approaches the $45M floor stipulated in the Cooperation Agreement with Caligan Partners. A new workforce reduction restructuring was initiated in Q1 2026 with $2.3M total expected cost ($1.6M recognized in Q1); $1.4M liability remains on balance sheet. The CEO transition resulted in $3.3M accelerated stock-based compensation in Q1 2026, which is non-cash but inflated SG&A. A full domestic deferred tax asset valuation allowance persists. Deferred compensation liability (RSU/PSU cash-settle) of $2.9M current is a modest but real obligation. The filing does not separately tag the CEO transition agreement's 18-month base salary obligation (paid over 24 months) in XBRL; this contingent cash outflow is discussed in MD&A and Note 13 but lacks a discrete XBRL balance sheet tag.
▼ Community Notes